Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinus sylvestris pollen, derived from the Scots pine, is utilized in clinical medicine primarily as an allergen extract for the diagnosis and treatment of IgE-mediated allergies. In diagnostic settings, such as skin prick testing, the pollen extract is used to identify sensitization in patients presenting with seasonal respiratory symptoms. In the context of allergen immunotherapy (AIT), also known as allergy vaccination, standardized extracts are administered to induce immunological tolerance, shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated regulatory profile. Although Pinus sylvestris is generally characterized by lower allergenic potential compared to deciduous trees like birch, it is a relevant allergen in regions with extensive coniferous forests. Beyond its clinical use, Pinus sylvestris pollen is also marketed as a dietary supplement (often simply termed 'pine pollen') for its purported antioxidant, anti-inflammatory, and androgenic properties, though these applications lack the rigorous clinical validation required for pharmaceutical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pinus sylvestris pollen.